Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Public ClinicalTrials.gov record NCT00333840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Study of STI571 Versus Interferon-α (IFN-α) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.
Study identification
- NCT ID
- NCT00333840
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,106 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2000 (Type not available)
- Primary completion
- Mar 2012 (Actual)
- Completion
- Mar 2012 (Actual)
- Last update posted
- Oct 14, 2013
2000 – 2012
United States locations
- U.S. sites
- 62
- U.S. states
- 34
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35294 | — |
| Novartis Investigative Site | Montgomery | Alabama | 36106 | — |
| Novartis Investigative Site | Tucson | Arizona | 85724 | — |
| Novartis Investigative Site | Berkeley | California | 94704 | — |
| Novartis Investigative Site | Campbell | California | 95008 | — |
| Novartis Investigative Site | Duarte | California | 91010 | — |
| Novartis Investigative Site | La Jolla | California | 92093-0960 | — |
| Novartis Investigative Site | Denver | Colorado | 80218 | — |
| Novartis Investigative Site | Miami | Florida | 33176-2197 | — |
| Novartis Investigative Site | Orlando | Florida | 32804 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30342 | — |
| Novartis Investigative Site | Honolulu | Hawaii | 96813 | — |
| Novartis Investigative Site | Chicago | Illinois | 60611 | — |
| Novartis Investigative Site | Chicago | Illinois | 60612 | — |
| Novartis Investigative Site | Chicago | Illinois | 60637 | — |
| Novartis Investigative Site | Decatur | Illinois | 62526 | — |
| Novartis Investigative Site | Beech Grove | Indiana | 46107 | — |
| Novartis Investigative Site | Witchita | Kansas | 67214 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40202 | — |
| Novartis Investigative Site | New Orleans | Louisiana | 70112 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21201 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02115 | — |
| Novartis Investigative Site | Worcester | Massachusetts | 01665 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48109 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202-2689 | — |
| Novartis Investigative Site | East Lansing | Michigan | 48910 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55455 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Billings | Montana | 59101 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68198-7681 | — |
| Novartis Investigative Site | Hackensack | New Jersey | 07601 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87109 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131 | — |
| Novartis Investigative Site | Farmington | New Mexico | 87131 | — |
| Novartis Investigative Site | Buffalo | New York | 14263 | — |
| Novartis Investigative Site | New York | New York | 10017 | — |
| Novartis Investigative Site | New York | New York | 10021 | — |
| Novartis Investigative Site | New York | New York | 10029 | — |
| Novartis Investigative Site | Syracuse | New York | 13210 | — |
| Novartis Investigative Site | Chapel Hill | North Carolina | 27599 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28203 | — |
| Novartis Investigative Site | Durham | North Carolina | 27710 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27157 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44195 | — |
| Novartis Investigative Site | Columbus | Ohio | 43210 | — |
| Novartis Investigative Site | Columbus | Ohio | 43215 | — |
| Novartis Investigative Site | Dayton | Ohio | 45429 | — |
| Novartis Investigative Site | Tulsa | Oklahoma | 74136 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15224 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15232 | — |
| Novartis Investigative Site | Providence | Rhode Island | 02903 | — |
| Novartis Investigative Site | Spartanburg | South Carolina | 29303 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38119 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37205 | — |
| Novartis Investigative Site | Dallas | Texas | 75235-9179 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84112 | — |
| Novartis Investigative Site | Seattle | Washington | 98109-1024 | — |
| Novartis Investigative Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00333840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2013 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00333840 live on ClinicalTrials.gov.